journal article·2021-10-19

Bipolar Imidazolium-Based Lipid Analogues for Artificial Archaeosomes

Simon Kriegler, Tiffany O. Paulisch, Tristan Wegner, Frank Glorius, Roland Winter

Langmuir· Volume 37· Issue 41
Publisher page

Abstract

Archaeal lipids have harvested biomedical and biotechnological interest because of their ability to form membranes with low permeability and enhanced temperature and pressure stability. Because of problems in isolating archaeal lipids, chemical synthesis appears to be a suitable means of producing model lipids that mimic the biological counterparts. Here, we introduce a new concept: we synthesized bipolar alkylated imidazolium salts of different chain lengths (BIm10-32) and studied their structure and lyotropic phase behavior. Furthermore, mixtures of the bolalipid analogues with phospholipid model biomembranes of diverse complexity were studied. DSC, fluorescence and FTIR spectroscopy, confocal fluorescence microscopy, DLS, SAXS, and TEM were used to reveal changes in lipid phase behavior, fluidity, the lipid's conformational order, and membrane morphology over a wide range of temperatures and for selected pressures. It could be shown that the long-chain BImN32 can form monolayer sheets. Integrated in phospholipid membranes, it reveals a fluidizing effect. Here, the two polar head groups, connected by a long alkyl chain, enable the integration into the bilayer. Interestingly, addition of BImN32 to fluid DPPC liposomes increased the lipid packing markedly, rendering the membrane system more stable at higher temperatures. The membrane system is also stable against compression as indicated by the high-pressure stability of the system, mimicking an archaeal lipid-like behavior. BImN32 incorporation into raft-like anionic model biomembranes led to marked changes in lateral membrane organization, topology, and fusogenicity of the membrane. Overall, it was found that long-chain imidazolium-based bolalipid analogues can help adjust membrane's biophysical properties, while the imidazolium headgroup provides the ability for crucial electrostatic interaction for vesicle fusion or selective interaction with membrane-related signaling molecules and polypeptides in a synthetically tractable manner. The results obtained may help to develop new approaches for rational design of extremophilic bolalipid-based liposomes for various applications, including delivery of drugs and vaccines.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Lipid Membrane Structure and Behavior · Supramolecular Self-Assembly in Materials · Force Microscopy Techniques and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry and Chemical Biology, Physical Chemistry I - Biophysical Chemistry, TU Dortmund University, Otto Hahn Str. 4a, D-44221 Dortmund, Germany

Institute of Organic Chemistry, University of Münster, Corrensstraße 40, 48149 Münster, Germany

Funding

Deutsche Forschungsgemeinschaft

References (51)

Show source-provided references
1. 10.1016/j.bpj.2014.07.03610.1016/j.bpj.2014.07.036 ↗
2. 10.1007/BF0033914010.1007/BF00339140 ↗
3. 10.1016/j.chemphyslip.2009.12.00610.1016/j.chemphyslip.2009.12.006 ↗
4. 10.3390/ijms2121838810.3390/ijms21218388 ↗
5. 10.1016/j.bpj.2010.09.06110.1016/j.bpj.2010.09.061 ↗
6. 10.3390/ijms2021530810.3390/ijms20215308 ↗
7. 10.1038/srep0746210.1038/srep07462 ↗
8. 10.1016/j.bbamem.2019.18313010.1016/j.bbamem.2019.183130 ↗
9. 10.1074/jbc.M60036920010.1074/jbc.M600369200 ↗
10. 10.1039/b517766a10.1039/b517766a ↗
11. 10.1016/j.bpc.2013.06.02010.1016/j.bpc.2013.06.020 ↗
12. 10.1016/j.cocis.2004.01.00510.1016/j.cocis.2004.01.005 ↗
13. 10.1021/ja710190p10.1021/ja710190p ↗
14. 10.1016/j.bpc.2011.06.01410.1016/j.bpc.2011.06.014 ↗
15. 10.1021/la990627z10.1021/la990627z ↗
16. 10.1016/j.colsurfa.2020.12497410.1016/j.colsurfa.2020.124974 ↗
17. 10.1021/cr030602b10.1021/cr030602b ↗
18. 10.1021/acs.chemmater.8b0099210.1021/acs.chemmater.8b00992 ↗
19. 10.1021/acs.langmuir.0c0152210.1021/acs.langmuir.0c01522 ↗
20. 10.3390/pharmaceutics1112064610.3390/pharmaceutics11120646 ↗
21. 10.3762/bjoc.13.9910.3762/bjoc.13.99 ↗
22. 10.1016/j.bpc.2018.10.00310.1016/j.bpc.2018.10.003 ↗
23. 10.1039/B703152A10.1039/B703152A ↗
24. 10.1002/chem.20160418210.1002/chem.201604182 ↗
25. 10.1021/acs.langmuir.6b0318210.1021/acs.langmuir.6b03182 ↗
26. 10.1007/s12551-017-0388-x10.1007/s12551-017-0388-x ↗
27. 10.1039/D0CP00801J10.1039/D0CP00801J ↗
28. 10.1002/chem.20200346610.1002/chem.202003466 ↗
29. 10.1021/acs.jpcb.8b0373310.1021/acs.jpcb.8b03733 ↗
30. 10.1021/acs.langmuir.9b0212810.1021/acs.langmuir.9b02128 ↗
31. 10.1039/c3cs60169b10.1039/c3cs60169b ↗
32. Mahalakshmi C. M. · Pharma Chem. · 2015 · 7 · 14
33. 10.1016/j.bbamem.2019.18310310.1016/j.bbamem.2019.183103 ↗
34. Cevc G. · 1993
35. 10.1038/4240810.1038/42408 ↗
36. 10.1016/j.abb.2004.03.02010.1016/j.abb.2004.03.020 ↗
37. 10.1021/ja107532q10.1021/ja107532q ↗
38. 10.1016/0005-2736(95)00233-210.1016/0005-2736(95)00233-2 ↗
39. 10.1146/annurev-biophys-052118-11560110.1146/annurev-biophys-052118-115601 ↗
40. Lakowicz J. R. · 200610.1007/978-0-387-46312-4 ↗
41. Winter R. · 201110.1007/978-3-8348-8143-4 ↗
42. 10.1524/zpch.1996.193.Part_1_2.15110.1524/zpch.1996.193.Part_1_2.151 ↗
43. 10.1039/C8CP07413E10.1039/C8CP07413E ↗
44. 10.1016/j.colsurfb.2018.10.00610.1016/j.colsurfb.2018.10.006 ↗
45. 10.1016/j.colsurfb.2019.03.02610.1016/j.colsurfb.2019.03.026 ↗
46. 10.1006/abio.1999.425210.1006/abio.1999.4252 ↗
47. 10.1016/j.bpc.2011.06.01410.1016/j.bpc.2011.06.014 ↗
48. 10.1194/jlr.M700479-JLR20010.1194/jlr.M700479-JLR200 ↗
49. 10.1371/journal.pone.004025410.1371/journal.pone.0040254 ↗
50. 10.1039/D0SC05990K10.1039/D0SC05990K ↗
51. 10.1016/j.bpj.2013.05.02410.1016/j.bpj.2013.05.024 ↗